Seres Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Seres Therapeutics

13/08/2024 14:52

* Seres Therapeutics Inc  MCRB.OQ  reported a quarterly
adjusted
loss of 22 cents​​ per share for the quarter ended in June,
lower than the same quarter last year, when the company reported
EPS of 36 cents.  The mean expectation of seven analysts for the
quarter was for a loss of 27 cents per share. Wall Street
expected results to range from -32 cents to -24 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Seres Therapeutics Inc's reported EPS for the quarter was
a loss
of 22 cents​.
    * The company reported a quarterly loss of $32.87 million.
    * Seres Therapeutics Inc shares had risen by 23.0% this
quarter and lost 36.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 4.3%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Seres
Therapeutics Inc is $1.25 
This summary was machine generated from LSEG data August 13 at
01:51 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.27          -0.22          Beat
 Mar. 31 2024      -0.34          -0.27          Beat
 Dec. 31 2023      -0.50          -0.32          Beat
 Sep. 30 2023      -0.50          -0.37          Beat